ATE348152T1 - Verfahren zum screening von diabetes- heilverfahren - Google Patents

Verfahren zum screening von diabetes- heilverfahren

Info

Publication number
ATE348152T1
ATE348152T1 AT01998193T AT01998193T ATE348152T1 AT E348152 T1 ATE348152 T1 AT E348152T1 AT 01998193 T AT01998193 T AT 01998193T AT 01998193 T AT01998193 T AT 01998193T AT E348152 T1 ATE348152 T1 AT E348152T1
Authority
AT
Austria
Prior art keywords
screening diabetes
cure
diabetes cure
screening
cell
Prior art date
Application number
AT01998193T
Other languages
English (en)
Inventor
Takahide Ohishi
Jun Takasaki
Mitsuyuki Matsumoto
Chou-Ku
Tetsu Saito
Masazumi Kamohara
Takatoshi Soga
Shigeru Yoshida
Yoshitaka Ueda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26605096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348152(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE348152T1 publication Critical patent/ATE348152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01998193T 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren ATE348152T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367349 2000-12-01
JP2001243841 2001-08-10

Publications (1)

Publication Number Publication Date
ATE348152T1 true ATE348152T1 (de) 2007-01-15

Family

ID=26605096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998193T ATE348152T1 (de) 2000-12-01 2001-11-30 Verfahren zum screening von diabetes- heilverfahren

Country Status (8)

Country Link
US (3) US20030180813A1 (de)
EP (2) EP1770159A1 (de)
JP (1) JP3438186B2 (de)
AT (1) ATE348152T1 (de)
AU (1) AU2002218509A1 (de)
DE (1) DE60125227T2 (de)
ES (1) ES2280435T3 (de)
WO (1) WO2002044362A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP2002130117A (ja) * 2000-10-18 2002-05-09 Mikuni Corp 電磁駆動型プランジャポンプ
EP1770159A1 (de) * 2000-12-01 2007-04-04 Astellas Pharma Inc. Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Diabetes
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
EP1538217A4 (de) * 2002-09-11 2006-09-27 Astellas Pharma Inc Screening-verfahren für insulingehalt-enhancer
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
WO2004084944A1 (ja) * 2003-03-25 2004-10-07 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005009469A1 (ja) * 2003-07-28 2005-02-03 Sumitomo Pharmaceuticals Co., Ltd. 新規血糖調節薬及びそのスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
NZ571110A (en) 2006-04-11 2011-03-31 Arena Pharm Inc Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
WO2008130581A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
WO2008130584A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
EP2152707B1 (de) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company An gpr119-g-protein gekoppelte [6,5]-bicyclische rezeptoragonisten
PL2170864T3 (pl) 2007-07-17 2012-02-29 Bristol Myers Squibb Co Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
JP2011528369A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
AU2009330208A1 (en) 2008-12-23 2011-08-04 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2382204B1 (de) 2008-12-23 2018-07-11 Merck Sharp & Dohme Corp. Pyrimidinderivate als gpcr-modulatoren zur verwendung bei der behandlung von obesitas und diabetes
EP2414348B1 (de) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclische piperidin- und piperazinderivate als gpcr-modulatoren zur behandlung von obesitas, diabetes und anderen stoffwechselkrankheiten
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
WO2011062885A1 (en) 2009-11-23 2011-05-26 Schering Corporation Fused bicyclic pyrimidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
EP2566862B1 (de) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl-analoga als gpr119-modulatoren
CN102971311B (zh) 2010-05-06 2015-07-08 百时美施贵宝公司 作为gpr119调节剂的二环杂芳基化合物
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
WO2012115640A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Liquid insulin- containing compositions and methods of making the same
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2016049200A1 (en) * 2014-09-24 2016-03-31 University Of Oregon Proteins increasing pancreatic beta cell number and methods of use
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL126750C (de) * 1960-12-05
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
IT1256191B (it) * 1992-12-03 1995-11-29 Impiego di lisolecitine nel trattamento della impotenza maschile e dell'alopecia e relative composizioni atte a tale impiego.
NZ510712A (en) 1998-10-13 2004-11-26 Arena Pharm Inc Non-endogenous, constitutively activated human G protein-coupled receptors
ATE301673T1 (de) 1998-11-20 2005-08-15 Arena Pharm Inc Menschliche, an ein g-protein gekoppelter rezeptor rup3 ohne bekannten ligand
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
JP2002535369A (ja) * 1999-01-29 2002-10-22 ベイヤー、カミル・エフ 糖尿病を治療するための組成物及び方法
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB9923177D0 (en) 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
EP1226250A2 (de) * 1999-11-03 2002-07-31 MERCK PATENT GmbH Gpcr-kd5 polypeptide und dns sequenzen davon
CA2388865A1 (en) 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors
CA2392961A1 (en) 1999-12-10 2001-06-14 Incyte Genomics, Inc. G-protein coupled receptors
EP1287133B1 (de) * 2000-05-18 2006-12-13 Bayer HealthCare AG Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
US20040067499A1 (en) 2000-08-04 2004-04-08 Tatsuya Haga Novel g protein-coupled receptor
EP1770159A1 (de) 2000-12-01 2007-04-04 Astellas Pharma Inc. Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Diabetes
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2002064789A1 (en) 2001-02-14 2002-08-22 Pharmacia & Upjohn Company Protein-coupled receptor

Also Published As

Publication number Publication date
AU2002218509A1 (en) 2002-06-11
JPWO2002044362A1 (ja) 2004-04-02
WO2002044362A1 (en) 2002-06-06
ES2280435T3 (es) 2007-09-16
EP1338651B1 (de) 2006-12-13
EP1338651A4 (de) 2005-04-27
US7662775B2 (en) 2010-02-16
EP1338651B9 (de) 2007-05-09
US20100144677A1 (en) 2010-06-10
EP1338651A1 (de) 2003-08-27
DE60125227D1 (de) 2007-01-25
JP3438186B2 (ja) 2003-08-18
EP1770159A1 (de) 2007-04-04
US20050136484A1 (en) 2005-06-23
US20030180813A1 (en) 2003-09-25
DE60125227T2 (de) 2007-09-20

Similar Documents

Publication Publication Date Title
DE60125227D1 (de) Verfahren zum screening von diabetes-heilverfahren
GB2217717B (en) Process for the production of porous membranes,the membranes produced thereby and their use as supporting matrices in test strips
ATE110415T1 (de) Verbessertes verfahren und apparat, um biologische substanzen in lebenden zellen einzuführen.
DE69229174D1 (de) Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
FI904534A0 (fi) Foerfarande och anordning foer amperometrisk diagnosanalys.
DE60029209D1 (de) Vorrichtung und verfahren zur einbringung von substanzen in eine zelle durch elektroporation
ATE418729T1 (de) Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
CH399779A (fr) Indicateur et son utilisation pour doser les substances dans les liquides biologiques
DE69427255D1 (de) Herstellung von Tetrazolium-Salz-Indikatoren enthaltenden diagnostischen Teststreifen
DE3788388D1 (de) Verfahren zur Herstellung eines REFETs oder eines CHEMFETs, sowie deren Herstellung.
WO2002042500A3 (en) Apparatus and method for electrophoretic microspot concentration
DK0681590T3 (da) Antikoagulerende sammensætning
DE602005025401D1 (de) Hes verfahren unter verwendung davon
DE60236530D1 (de) Verfahren zur vorbehandlung von proben zur bestimmung von verzuckerten aminen, sowie verfahren zur bestimmung von verzuckerten aminen
AU2003302816A1 (en) Method for manufacturing tool for analysis
ATE483975T1 (de) Behälter und kits zur bestimmung von zellfunktionen und verfahren zu deren bestimmung
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
SE437303B (sv) Forfarande for on-line-metning av koncentrationen av en analyt i en behallare, samt apparat for genomforande av forfarandet
ES2089132T3 (es) Analisis de pelo.
DE69715034D1 (de) Verfahren zur herstellung von dem anaphase-fördernden komplex
Tsuda et al. A new type of N-nitrosamino acid, N-nitroso-L-thioproline and N-nitroso-L-methylthioprolines, found in human urine as major N-nitroso compounds
CA2004068A1 (en) Hair analysis method
Esaka et al. Separation of amino acid—oxazole derivatives of the redox coenzyme pyrroloquinoline quinone by capillary zone electrophoresis
ATE440278T1 (de) Verfahren und vorrichtung zur charakterisierung von osi-material
IS3331A7 (is) Aðferð til að nota skönnunarsmásjá og myndgreini til efnagreingingar, með því að mæla meðal sætistölu frumefna í efnafösum, sem innihalda létt frumefni.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1338651

Country of ref document: EP